Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 23.73 CNY -1.25% Market Closed
Market Cap: 38.7B CNY
Have any thoughts about
Humanwell Healthcare Group Co Ltd?
Write Note

Humanwell Healthcare Group Co Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Humanwell Healthcare Group Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Humanwell Healthcare Group Co Ltd
SSE:600079
Other Receivables
ÂĄ1.7B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
9%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Receivables
ÂĄ111m
CAGR 3-Years
-38%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Receivables
ÂĄ297.6m
CAGR 3-Years
19%
CAGR 5-Years
8%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Receivables
ÂĄ1.3B
CAGR 3-Years
-23%
CAGR 5-Years
3%
CAGR 10-Years
0%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Receivables
ÂĄ3.1B
CAGR 3-Years
33%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Receivables
ÂĄ74.5m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
38.7B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
37.19 CNY
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Humanwell Healthcare Group Co Ltd's Other Receivables?
Other Receivables
1.7B CNY

Based on the financial report for Sep 30, 2024, Humanwell Healthcare Group Co Ltd's Other Receivables amounts to 1.7B CNY.

What is Humanwell Healthcare Group Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 10Y
9%

Over the last year, the Other Receivables growth was 12%. The average annual Other Receivables growth rates for Humanwell Healthcare Group Co Ltd have been -3% over the past three years , -7% over the past five years , and 9% over the past ten years .

Back to Top